MedTrace Logo

Prevalence of Perimyocarditis After Covid-19 Vaccine

NCT04865900 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2021-04-29

No results posted yet for this study

Summary

The aim of this study is to determine whether there is a higher prevalence of perimyocarditis after undergoing vaccination for Covid-19.

Conditions

  • Perimyocarditis
  • Covid19

Interventions

DIAGNOSTIC_TEST

Laboratory Blood Tests

Blood tests to determine liver and kidney functioning, total blood count, and troponin levels

DIAGNOSTIC_TEST

ECG

ECG to determine heart rate and functioning

DIAGNOSTIC_TEST

PCR

PCR test to determine whether patient has Covid19

DIAGNOSTIC_TEST

Antibody test

Antibody test to determine level of antibodies to Covid19

DIAGNOSTIC_TEST

Echocardiography

If Troponin level elevated echocardiography to determine heart function

DIAGNOSTIC_TEST

MRI

If Troponin level elevated MRI to determine heart function

Sponsors & Collaborators

  • Hillel Yaffe Medical Center

    lead OTHER_GOV

Principal Investigators

  • Saif Abu-Moch, MD · Hillel Yaffe Medical Center

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-09
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04865900 on ClinicalTrials.gov